User profiles for Reto A. Schuepbach
 | Reto SchuepbachUniversity Hospital Zurich, University Zurich, Switzerland Verified email at usz.ch Cited by 12015 |
Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases
DM Heuberger, RA Schuepbach - Thrombosis journal, 2019 - Springer
Inflammatory diseases have become increasingly prevalent with industrialization. To address
this, numerous anti-inflammatory agents and molecular targets have been considered in …
this, numerous anti-inflammatory agents and molecular targets have been considered in …
Outcome of extracorporeal membrane oxygenation as a bridge to lung transplantation: an institutional experience and literature review
I Inci, S Klinzing, D Schneiter, RA Schuepbach… - …, 2015 - journals.lww.com
Background Extracorporeal life support (ECLS) as a bridge to lung transplantation (LuTx) is
a promising option for patients with end-stage lung disease on the transplant waiting list. We …
a promising option for patients with end-stage lung disease on the transplant waiting list. We …
Endothelial cell infection and endotheliitis in COVID-19
Cardiovascular complications are rapidly emerging as a key threat in coronavirus disease
2019 (COVID-19) in addition to respiratory disease. The mechanisms underlying the …
2019 (COVID-19) in addition to respiratory disease. The mechanisms underlying the …
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
…, AS Zinkernagel, RA Schuepbach… - The Journal of …, 2007 - Am Soc Clin Investig
Iron is essential for many biological processes, including oxygen delivery, and its supply is
tightly regulated. Hepcidin, a small peptide synthesized in the liver, is a key regulator of iron …
tightly regulated. Hepcidin, a small peptide synthesized in the liver, is a key regulator of iron …
Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19 …
…, J Montomoli, F Roche-Campo, RA Schuepbach… - …, 2020 - thelancet.com
Background Coronavirus disease 2019 (COVID-19) is associated with a high disease
burden with 10% of confirmed cases progressing towards critical illness. Nevertheless, the …
burden with 10% of confirmed cases progressing towards critical illness. Nevertheless, the …
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
H Frebel, V Nindl, RA Schuepbach… - Journal of Experimental …, 2012 - rupress.org
The inhibitory programmed death 1 (PD-1)–programmed death ligand 1 (PD-L1) pathway
contributes to the functional down-regulation of T cell responses during persistent systemic …
contributes to the functional down-regulation of T cell responses during persistent systemic …
SARS-CoV-2 leads to a small vessel endotheliitis in the heart
…, G Cathomas, F Ruschitzka, RA Schuepbach… - …, 2021 - thelancet.com
Background SARS-CoV-2 infection (COVID-19 disease) can induce systemic vascular
involvement contributing to morbidity and mortality. SARS-CoV-2 targets epithelial and …
involvement contributing to morbidity and mortality. SARS-CoV-2 targets epithelial and …
[PDF][PDF] Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically ill COVID-19 patients
The impact of secondary bacterial infections (superinfections) in coronavirus disease 2019 (COVID-19)
is not well understood. In this prospective, monocentric cohort study, we aim to …
is not well understood. In this prospective, monocentric cohort study, we aim to …
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells
C Feistritzer, RA Schuepbach, LO Mosnier… - Journal of biological …, 2006 - ASBMB
Activated protein C (APC) has endothelial barrier protective effects that require binding to
endothelial protein C receptor (EPCR) and cleavage of protease activated receptor-1 (PAR1) …
endothelial protein C receptor (EPCR) and cleavage of protease activated receptor-1 (PAR1) …
Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease
…, DA Hofmaenner, TC Scheier, RA Schuepbach… - PLoS …, 2022 - journals.plos.org
Autoantibodies neutralizing the antiviral action of type I interferons (IFNs) have been
associated with predisposition to severe Coronavirus Disease 2019 (COVID-19). Here, we …
associated with predisposition to severe Coronavirus Disease 2019 (COVID-19). Here, we …
